Cardiology

Heart disease remains the leading cause of illness and death among people with diabetes. However, one of the most concerning complications, diabetic cardiomyopathy, often develops quietly for years before symptoms emerge. During this silent phase, routine echocardiograms frequently show a normal ejection fraction, creating a false sense of reassurance. Fortunately, …

The treatment landscape for type 2 diabetes has changed dramatically over the past decade. While selective SGLT2 inhibitors have become a cornerstone of diabetes management because of their proven cardiovascular and kidney benefits, researchers are now exploring the added potential of dual SGLT1/2 inhibitor therapy for people with diabetes. By …

Most people think diabetes-related blood vessel damage begins only after years of high blood sugar. However, scientists are uncovering evidence that injury may start much earlier, in a structure so thin it cannot be seen during a routine medical exam. This microscopic layer, known as the endothelial glycocalyx, acts as …

For many people with diabetes, lowering LDL cholesterol is just as important as controlling blood sugar. However, not everyone reaches their cholesterol goals with statins alone, and injectable PCSK9 inhibitors can be inconvenient or intimidating. Now, a new option has arrived. The FDA has approved the first oral PCSK9 inhibitor, …

For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …

Not long ago, diabetes management focused primarily on controlling blood glucose levels. Today, that approach has evolved dramatically as cardiologists and endocrinologists increasingly work together to reduce cardiovascular risk. Thanks to groundbreaking cardiovascular outcome trials (CVOTs), clinicians now understand that treating type 2 diabetes means protecting the heart, kidneys, and …

For years, artificial sweeteners have been promoted as an important strategy for reducing sugar intake in people with diabetes. They help lower carbohydrate intake, reduce post-meal glucose spikes, and support weight management without adding calories. However, recent research has challenged the long-held assumption that all non-nutritive sweeteners are metabolically neutral. …

Choosing the right treatment for patients with both diabetes and heart disease can feel like walking a tightrope. With evolving evidence, the role of incretin therapy in cardiovascular disease management is now at the center of clinical decision-making. Recent cardiovascular outcomes trials have shifted how clinicians think about therapy selection, …

In recent years, the role of incretin therapy in cardiovascular disease management has gained attention as new outcomes data reshape how clinicians approach high-risk patients. But should treatment choices really change based on these findings? As evidence evolves, many providers are reconsidering which therapies deliver both glycemic control and cardiovascular …

The relationship between GLP-1 therapies and atrial fibrillation is an emerging topic in diabetes care, raising an important question: could medications designed to protect the heart also influence its rhythm? Patients with diabetes already face a higher risk of atrial fibrillation, so understanding how these GLP-1 receptor agonists affect cardiac …